MedTrace Logo

A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

NCT04844359 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 137

Last updated 2026-04-09

No results posted yet for this study

Summary

Up to 150 patients with hypersensitivity pneumonitis will be enrolled at 7 clinical centers across the United States. Patients will be followed for 24 months to determine if biomarkers in the blood can predict disease progression.

Conditions

  • Hypersensitivity Pneumonitis

Sponsors & Collaborators

  • University of California, Davis

    collaborator OTHER

  • Mayo Clinic

    collaborator OTHER

  • University of Chicago

    collaborator OTHER

  • University of Texas Southwestern Medical Center

    collaborator OTHER

  • University of Arizona

    collaborator OTHER

  • University of Utah

    collaborator OTHER

  • National Jewish Health

    lead OTHER

Principal Investigators

  • Evans Fernández, MD, MS · National Jewish Health

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-06
Primary Completion
2026-07-30
Completion
2026-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04844359 on ClinicalTrials.gov